{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.25B vs. cons $3.23B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.93 vs. cons $4.85",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 JOURNAVX revenue",
      "prediction": "MISS",
      "answer": "pred ~$51M vs. cons $55M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 total revenue",
      "prediction": "UNCHANGED",
      "answer": "guide ~$13.03B midpoint vs. cons $13.05B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 non-CF product revenue",
      "prediction": "LOWER",
      "answer": "guide ~$500M floor vs. cons $540M (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP R&D, acquired IPR&D and SG&A",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.70B midpoint vs. cons $5.70B (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -2.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.4,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Predicted day-5 residual of -3.4% vs. day-1 residual of -2.3%: an EPS beat is likely to be outweighed by soft JOURNAVX monetization, a non-CF guide below the ~$540M consensus, demanding second-half revenue math, and Crinetics-related dilution that pressures out-period estimates.",
  "day5_confidence": "MEDIUM"
}